FrancophonIA/ELRC3.0 huggingface dataset:
English: Primary Composite Endpoint [First Event of CV Death, Nonfatal MI and Nonfatal Stroke]
Croatian: Primarni kompozitni ishod [prvi događaj KV smrti, IM bez smrtnog ishoda i moždanog udara bez smrtnog ishoda] Kardiovaskularna smrt* Infarkt miokarda bez smrtnog ishoda Moždani udar bez smrtnog ishoda 29 (1,1)
English: NAME OF THE MEDICINAL PRODUCT Incresync 12.5 mg/45 mg tablets alogliptin/pioglitazone
Croatian: NAZIV LIJEKA Incresync 12,5 mg/45 mg tablete alogliptin/pioglitazon
English: Pale red, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “12.5/45” printed in red ink on one side.
Croatian: Okrugle (promjera približno 8,7 mm), bikonveksne filmom obložene tablete, blijedo crvene boje s oznakama „A/P“ i „12,5/45“ otisnutim crvenom tintom na jednoj strani.
English: Pale peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “12.5/30” printed in red ink on one side.
Croatian: Okrugle (promjera približno 8,7 mm), bikonveksne filmom obložene tablete boje breskve s oznakama „A/P“ i „12,5/30“ otisnutim crvenom tintom na jednoj strani.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 30 mg pioglitazone (as hydrochloride).
Croatian: Jedna tableta sadrži 12,5 mg alogliptina (u obliku alogliptinbenzoata) i 30 mg pioglitazona (u obliku pioglitazonklorida)
English: NAME OF THE MEDICINAL PRODUCT Incresync 12.5 mg/30 mg tablets alogliptin/pioglitazone
Croatian: NAZIV LIJEKA Incresync 12,5 mg/30 mg tablete alogliptin/pioglitazon
English: Red, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “25/45” printed in grey ink on one side.
Croatian: Okrugle (promjera približno 8,7 mm), bikonveksne filmom obložene tablete crvene boje s oznakama „A/P“ i „25/45“ otisnutim sivom tintom na jednoj strani.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 25 mg alogliptin (as benzoate) and 45 mg pioglitazone (as hydrochloride).
Croatian: Jedna tableta sadrži 25 mg alogliptina (u obliku alogliptinbenzoata) i 45 mg pioglitazona (u obliku pioglitazonklorida)
English: Nervous system disorders headache common common hypoaesthesia common insomnia uncommon
Croatian: Poremećaji živčanog sustava Hipoestezija
English: Treatment-corrected change from baseline in HbA1c (%)†
Croatian: Promjena od početne vrijednosti HbA1c korigirana za liječenje (1-strani CI)
English: NAME OF THE MEDICINAL PRODUCT Incresync 25 mg/45 mg tablets alogliptin/pioglitazone
Croatian: NAZIV GOTOVOG LIJEKA Incresync 25 mg/45 mg tablete alogliptin/pioglitazon
English: Each tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin and 30 mg pioglitazone.
Croatian: Jedna tableta sadrži alogliptinbenzoat i pioglitazonklorid koji odgovaraju 25 mg alogliptina i 30 mg pioglitazona.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 25 mg alogliptin (as benzoate) and 30 mg pioglitazone (as hydrochloride).
Croatian: Jedna tableta sadrži 25 mg alogliptina (u obliku alogliptinbenzoata) i 30 mg pioglitazona (u obliku pioglitazonklorida)
English: Each12.5 mg/30 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 12.5 mg alogliptin and 30 mg pioglitazone.
Croatian: Svaka filmom obložena tableta od 12,5 mg/30 mg sadrži alogliptinbenzoat i pioglitazonklorid koji odgovaraju 12,5 mg alogliptina i 30 mg pioglitazona.
English: Uncommon (may affect up to 1 in 100 people): - Symptoms of bladder cancer including blood in your urine, pain when urinating or a sudden need to urinate.
Croatian: • Simptomi raka mokraćnog mjehura uključujući krv u mokraći, bol pri mokrenju ili neodgodivu potrebu za mokrenjem.
English: Placebo-corrected change from baseline in HbA1c (%)†
Croatian: Promjena od početne vrijednosti HbA1c (%) korigirana za placebo (2-strani 95% CI)
English: - The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), macrogol 8000, shellac, carnauba wax and glycerol mono-oleate.
Croatian: - Drugi sastojci su: manitol, mikrokristalična celuloza, hidroksipropilceluloza, umrežena karmelozanatrij, magnezijev stearat, laktoza hidrat, hipromeloza, talk, titanijev dioksid (E171), žuti željezov oksid (E172), crveni željezov oksid (E172), makrogol 8000, šelak, karnauba vosak i glicerolmonooleat.
English: Renal impairment
Croatian: Učestalost nuspojava
English: - The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), macrogol 8000, shellac and black iron oxide (E172).
Croatian: - Drugi sastojci su: manitol, mikrokristalična celuloza, hidroksipropilceluloza, umrežena karmelozanatrij, magnezijev stearat, laktoza hidrat, hipromeloza, talk, titanijev dioksid (E171), žuti željezov oksid (E172), crveni željezov oksid (E172), makrogol 8000, šelak i crni željezov oksid (E172).
English: Peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “25/30” printed in grey ink on one side.
Croatian: Okrugle (promjera približno 8,7 mm), bikonveksne filmom obložene tablete boje breskve s oznakama „A/P“ i „25/30“ otisnutim sivom tintom na jednoj strani.
English: In particular tell your doctor or pharmacist if you are taking any of the following: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections)
Croatian: • rifampicin (koristi se za liječenje tuberkuloze i drugih infekcija).
English: Magyarország Takeda Pharma Kft. Tel: +361 2707030
Croatian: Takeda Pharmaceuticals Czech Republic s.r.o. Tel: +420 234722722
English: NAME OF THE MEDICINAL PRODUCT Incresync 25 mg/45 mg film-coated tablets alogliptin/pioglitazone
Croatian: Incresync 25 mg/45 mg filmom obložene tablete alogliptin/pioglitazon
English: Hepatic impairment
Croatian: • glavobolja
English: EU/1/13/842/001 10 film-coated tablets EU/1/13/842/002 14 film-coated tablets EU/1/13/842/003 28 film-coated tablets EU/1/13/842/004 30 film-coated tablets EU/1/13/842/005 56 film-coated tablets EU/1/13/842/006 60 film-coated tablets EU/1/13/842/007 90 film-coated tablets EU/1/13/842/008 98 film-coated tablets EU/1/13/842/009 100 film-coated tablets
Croatian: EU/1/13/842/001 10 filmom obloženih tableta EU/1/13/842/002 14 filmom obloženih tableta EU/1/13/842/003 28 filmom obloženih tableta EU/1/13/842/004 30 filmom obloženih tableta EU/1/13/842/005 56 filmom obloženih tableta EU/1/13/842/006 60 filmom obloženih tableta EU/1/13/842/007 90 filmom obloženih tableta EU/1/13/842/008 98 filmom obloženih tableta EU/1/13/842/009 100 filmom obloženih tableta
English: Takeda Pharma AS Tel: +372 6177 669
Croatian: Takeda Pharma AS Tel: ++372 6177 669 info@nycomed.ee
English: - The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium dioxide (E171), red iron oxide (E172), macrogol 8000, shellac and black iron oxide (E172).
Croatian: - Drugi sastojci su: manitol, mikrokristalična celuloza, hidroksipropilceluloza, umrežena karmelozanatrij, magnezijev stearat, laktoza hidrat, hipromeloza, talk, titanijev dioksid (E171), crveni željezov oksid (E172), makrogol 8000, šelak i crni željezov oksid (E172).
English: EU/1/13/842/019 10 film-coated tablets EU/1/13/842/020 14 film-coated tablets EU/1/13/842/021 28 film-coated tablets EU/1/13/842/022 30 film-coated tablets EU/1/13/842/023 56 film-coated tablets EU/1/13/842/024 60 film-coated tablets EU/1/13/842/025 90 film-coated tablets EU/1/13/842/026 98 film-coated tablets EU/1/13/842/027 100 film-coated tablets
Croatian: EU/1/13/842/019 10 filmom obloženih tableta EU/1/13/842/020 14 filmom obloženih tableta EU/1/13/842/021 28 filmom obloženih tableta EU/1/13/842/022 30 filmom obloženih tableta EU/1/13/842/023 56 filmom obloženih tableta EU/1/13/842/024 60 filmom obloženih tableta EU/1/13/842/025 90 filmom obloženih tableta EU/1/13/842/026 98 filmom obloženih tableta EU/1/13/842/027 100 filmom obloženih tableta
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Croatian: Nositelj odobrenja za stavljanje lijeka u promet i proizvođač
English: NAME OF THE MEDICINAL PRODUCT Incresync 25 mg/30 mg film-coated tablets alogliptin/pioglitazone
Croatian: Incresync 25 mg/30 mg filmom obložene tablete alogliptin/pioglitazon
English: The overall incidence of episodes of severe hypoglycaemia was comparable in patients treated with 25 mg alogliptin or 12.5 mg alogliptin,
Croatian: Najčešća nuspojava u bolesnika liječenih s 25 mg alogliptina bila je glavobolja.
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription.
Croatian: DODATAK II A. PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET B. UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU C. OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET D.
English: EU/1/13/842/010 10 film-coated tablets EU/1/13/842/011 14 film-coated tablets EU/1/13/842/012 28 film-coated tablets EU/1/13/842/013 30 film-coated tablets EU/1/13/842/014 56 film-coated tablets EU/1/13/842/015 60 film-coated tablets EU/1/13/842/016 90 film-coated tablets EU/1/13/842/017 98 film-coated tablets EU/1/13/842/018 100 film-coated tablets
Croatian: EU/1/13/842/010 10 filmom obloženih tableta EU/1/13/842/011 14 filmom obloženih tableta EU/1/13/842/012 28 filmom obloženih tableta EU/1/13/842/013 30 filmom obloženih tableta EU/1/13/842/014 56 filmom obloženih tableta EU/1/13/842/015 60 filmom obloženih tableta EU/1/13/842/016 90 filmom obloženih tableta EU/1/13/842/017 98 filmom obloženih tableta EU/1/13/842/018 100 filmom obloženih tableta
English: Mannitol
Croatian: Takeda
English: NAME OF THE MEDICINAL PRODUCT Incresync 12.5 mg/45 mg film-coated tablets alogliptin/pioglitazone
Croatian: Incresync 12,5 mg/45 mg filmom obložene tablete alogliptin/pioglitazon
English: EU/1/13/842/028 10 film-coated tablets EU/1/13/842/029 14 film-coated tablets EU/1/13/842/030 28 film-coated tablets EU/1/13/842/031 30 film-coated tablets EU/1/13/842/032 56 film-coated tablets EU/1/13/842/033 60 film-coated tablets EU/1/13/842/034 90 film-coated tablets EU/1/13/842/035 98 film-coated tablets EU/1/13/842/036 100 film-coated tablets
Croatian: EU/1/18/842/028 10 filmom obloženih tableta EU/1/13/842/029 14 filmom obloženih tableta EU/1/13/842/030 28 filmom obloženih tableta EU/1/13/842/031 30 filmom obloženih tableta EU/1/13/842/032 56 filmom obloženih tableta EU/1/13/842/033 60 filmom obloženih tableta EU/1/13/842/034 90 filmom obloženih tableta EU/1/13/842/035 98 filmom obloženih tableta EU/0/00/000/036 100 filmom obloženih tableta
English: Carnauba wax
Croatian: Makularni edem
English: NAME OF THE MEDICINAL PRODUCT Incresync 12.5 mg/30 mg film-coated tablets alogliptin/pioglitazone
Croatian: Incresync 12,5 mg/30 mg filmom obložene tablete alogliptin/pioglitazon
English: What is Vizamyl and what is it used for?
Croatian: Što je Vizamyl i za što se koristi?
English: The full EPAR and risk management plan summary for Vizamyl can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Vizamyl nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A later re-analysis looked again at data from the original 68 patients together with results from others who had died after the end of the original study, making a total of 106 patients.
Croatian: Kasnija ponovna analiza ponovno je istražila podatke izvornih 68 bolesnika zajedno s rezultatima ostalih bolesnika koji su umrli nakon završetka izvornog ispitivanja, što čini ukupno 106 bolesnika.
English: What are the risks associated with Vizamyl?
Croatian: Koji su rizici povezani s lijekom Vizamyl?
English: What measures are being taken to ensure the safe and effective use of Vizamyl?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Vizamyl?
English: It is not intended to provide practical advice on how to use Vizamyl.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Vizamyl.
English: In this re-analysis most readers could interpret the scans with a sensitivity of around 91% (91% of patients who had plaques were identified) and a specificity of 90% (90% of patients without plaques were correctly rated as not having plaques).
Croatian: U ovoj posljednjoj analizi većina osoba koja je očitavala snimke mogla je tumačiti snimke s osjetljivošću od otprilike 91% (91% bolesnika kojima su identificirani plakovi) i specifičnost od 90% (u 90% bolesnika bez plakova ispravno je utvrđeno da nemaju plakova).
English: In addition, the company that markets Vizamyl will provide access to a training course for all nuclearmedicine physicians expected to use this product in the European Union, in order to ensure accurate and reliable reading of the PET scan images.
Croatian: Nadalje, tvrtka koja stavlja lijek u promet Vizamyl omogućit će pristup tečajevima za obuku za sve liječnike nuklearne medicine za koje se očekuje da će koristiti ovaj proizvod u Europskoj uniji, kako bi se osiguralo točno i pouzdano očitavanje slika PET snimaka.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Vizamyl on 22 August 2014.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Vizamyl na snazi u Europskoj uniji od 22. kolovoza 2014.
English: Vizamyl delivers a very low amount of radiation which poses a very low risk of cancer or any hereditary abnormalities.
Croatian: Vizamyl isporučuje vrlo malu količinu zračenja što predstavlja vrlo mali rizik od raka ili bilo kakvih nasljednih abnormalnosti.
English: This is a summary of the European public assessment report (EPAR) for Vizamyl.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Vizamyl.
English: This means that the PET scans correctly identified as positive between 81-93% of the patients who had significant amounts of plaques in their brain.
Croatian: To znači da su PET snimke ispravno identificirale pozitivno 81-93% bolesnika koji su imali značajne količine plakova u mozgu.
English: This is considered a significant improvement in the diagnosis of patients with memory problems who are being evaluated for Alzheimer's disease and other types of dementia.
Croatian: To se smatra značajnim poboljšanjem u dijagnosticiranju bolesnika s problemima pamćenja koji se evaluiraju zbog Alzheimerove bolesti i drugih tipova demencije.
English: Doctors will therefore need to use the scan together with a clinical evaluation.
Croatian: Stoga liječnici moraju koristiti snimke zajedno s drugim sredstvima kliničkog ocjenjivanja.
English: A risk management plan has been developed to ensure that Vizamyl is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Vizamyl.
English: The most common side effects with Vizamyl (seen in between 1 and 10 patients in 100) are flushing (reddening of the skin) and increased blood pressure.
Croatian: Najčešće nuspojave lijeka Vizamyl (mogu se javiti kod 1 do 10 osoba na 100 bolesnika) su crvenilo (crvenilo kože) i povišeni krvni tlak.
English: The type of scan used with Vizamyl is called positron-emission tomography (PET).
Croatian: Tip snimke koji se koristi s lijekom Vizamyl naziva se i pozitronska emisijska tomografija (PET).
English: In addition, the usefulness of Vizamyl in predicting the development of Alzheimer's disease in patients with memory problems or in monitoring patients' response to treatment has not been established.
Croatian: Nadalje, iskoristivost lijeka Vizamyl u predviđanju razvoja Alzheimerove bolesti u bolesnika s problemima pamćenja ili praćenju odgovora bolesnika na liječenje nije utvrđeno.
English: When the results of the autopsies were compared with the PET scans, the scans were shown to have a sensitivity between 81-93%.
Croatian: Usporedbom rezultata autopsija s PET snimkama dokazana je osjetljivost snimaka između 81-93%.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Vizamyl's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Vizamyl nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: Why is Vizamyl approved?
Croatian: Zašto je Vizamyl odobren?
English: The CHMP did however note that, due to the limited effects of currently available treatments for Alzheimer's disease, there is no strong evidence of an immediate improvement in the management of patients or in patient outcomes following PET scans with Vizamyl.
Croatian: No, CHMP je ipak napomenuo da uslijed ograničenog djelovanja trenutno dostupnog liječenja Alzheimerove bolesti ne postoje čvrsti dokazi za neposredno poboljšanje održavanog stanja bolesnika niti ishode kod bolesnika nakon PET snimaka s lijekom Vizamyl.
English: There is, however, a risk of false positive results (when patients without plaques are rated as positive), therefore Vizamyl scans should not be used on their own to diagnose dementia, but together with a clinical evaluation of the patient.
Croatian: No, postoji rizik lažnih pozitivnih rezultata (u slučaju kada su bolesnici bez plakova ocijenjeni kao pozitivni), stoga se snimke s lijekom Vizamyl ne smiju koristiti samostalno u dijagnosticiranju demencije, već zajedno s kliničkom evaluacijom bolesnika.
English: Patients should discuss the results of their PET scan with their doctor.
Croatian: Bolesnici trebaju o rezultatima svojih PET snimaka razgovarati sa svojim liječnikom.
English: The radiation it emits can be detected on the PET scan, enabling doctors to see whether or not significant amount of plaques are present.
Croatian: Zračenje koje emitira može se otkriti PET snimanjem, što omogućuje liječnicima da uoče jesu li prisutne značajne količine plaka.
English: In terms of safety, Vizamyl involves exposure of the patient to small amounts of radiation, which is in the range of other approved radiopharmaceuticals, and the safety profile is therefore acceptable.
Croatian: U smislu sigurnosti, Vizamyl obuhvaća izlaganje bolesnika malim količinama zračenja unutar raspona drugih odobreni radiofarmaceutika, te je sigurnosni profil stoga prihvatljiv.
English: If few or no β-amyloid plaques are seen in the PET scan (a negative scan), the patient is unlikely to have Alzheimer's disease.
Croatian: Ako se uoči mala količina β-amiloidnih plakova ili ih se ne uoči na PET snimci (negativna snimka), nije izgledno da bolesnik ima Alzheimerovu bolest.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vizamyl, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Vizamyl nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: The active substance in Vizamyl, flutemetamol (18F), is a radiopharmaceutical that emits low amounts of radiation and works by targeting and attaching to β-amyloid plaques in the brain.
Croatian: Djelatna tvar lijeka Vizamyl, flutemetamol (18F), je radiofarmaceutik koji emitira male količine zračenja i djeluje ciljajući i vezujući se na β-amiloidne plakove u mozgu.
English: Vizamyl is available as a solution that is given by injection into a vein, about 90 minutes before obtaining an image from a PET scan.
Croatian: Vizamyl je dostupan kao otopina koja se primjenjuje injekcijom u venu, otprilike 90 minuta prije oslikavanja PET snimanjem.
English: Vizamyl was investigated in one main study in 176 patients nearing the end of their lives who had consented to autopsies when they died, in order to prove conclusively whether or not they had significant amounts of β-amyloid plaques in their brains.
Croatian: Vizamyl je ispitan u jednom glavnom ispitivanju u 176 bolesnika koji su se nalazili pred kraj života te koji su dali suglasnost za obdukciju nakon smrti, kako bi se zaključno dokazalo jesu li imali značajne količine β-amiloidnih plakova u mozgovima.
English: However, a positive scan on its own is not sufficient to make a diagnosis in patients with memory problems, as plaques may be seen in patients with different types of dementias as well as in older people with no symptoms.
Croatian: No, samo pozitivna snimka nije dovoljna za donošenje dijagnoze u bolesnika s problemima pamćenja, budući da se plakovi mogu uočiti u bolesnika s različitim tipovima demencija kao i u starijih osoba bez simptoma.
English: For more information about treatment with Vizamyl, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Vizamyl pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: The study looked at the sensitivity of the PET scans (how well scans identified patients who had significant amounts of plaques in the brain) when interpreted by skilled readers.
Croatian: Ispitivanje je istražilo osjetljivost PET snimaka (koliko su dobro snimke identificirale bolesnike koji su imali značajne količine plakova u mozgu) nakon što su ih očitali kvalificirani liječnici.
English: Other information about Vizamyl
Croatian: Ostale informacije o lijeku Vizamyl
English: How does Vizamyl work?
Croatian: Kako djeluje Vizamyl?
English: The Committee noted that PET scans with Vizamyl have a high sensitivity and specificity for detecting a significant amount of beta-amyloid plaques in the brain, and that scans closely reflect what was seen at autopsy.
Croatian: Odbor je zaključio da PET snimke s lijekom Vizamyl imaju visoki stupanj osjetljivosti i specifičnosti za otkrivanje količine beta-amiloidnih plakova u mozgu, te da snimke precizno prikazuju ono što je uočeno na biopsiji.
English: What benefits of Vizamyl have been shown in studies?
Croatian: Koje su koristi lijeka Vizamyl utvrđene u ispitivanjima?
English: At the end of the study, 68 had autopsies carried out on them to prove conclusively whether or not they had significant amounts of β-amyloid plaques in their brains.
Croatian: Po završetku ispitivanja, nad 68 bolesnika provedena je obdukcija kako bi se zaključno dokazalo jesu li imali značajne količine β-amiloidnih plakova u mozgovima.
English: After the image is obtained, it is read by nuclear medicine physicians specifically trained in interpreting PET scans with Vizamyl.
Croatian: Nakon što se slika snimi, sliku treba pročitati liječnik nuklearne medicine koji je posebno obučen za očitavanje PET snimaka snimljenih lijekom Vizamyl.
English: β-amyloid plaques are deposits sometimes present in the brain of people with memory problems caused by dementia (such as Alzheimer's disease, Lewy-body dementia and Parkinson's disease dementia) and also in the brain of some older people with no symptoms of dementia.
Croatian: Vizamyl se koristi tijekom snimanja mozga u bolesnika s problemima pamćenja tako da liječnici mogu vidjeti imaju li bolesnici značajne količine β-amiloidnih plakova u mozgu. β-amiloidni plakovi su naslage koje su ponekad prisutne u mozgu osobe koja pati od problema pamćenja uzrokovanih demencijom (poput Alzheimerove bolesti, demencije s Lewy tjelešcima i demencije s Parkinsonovom bolesti) te također u mozgu određenih starijih osoba bez simptoma demencije.